Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis
详细信息 查看全文
- 作者：Da Hyun Leea ; b ; 1 ; Dai Hoon Hanc ; 1 ; Ki Taek Nama ; b ; Jeong Su Parkb ; Soo Hyun Kimd ; Milim Leed ; Gyuri Kimd ; Byung Soh Minc ; Bong-Soo Chad ; Yu Seol Leeb ; Su Haeng Sungb ; Haengdueng Jeonga ; b ; Hye Won Jib ; Moon Joo Leeb ; Jae Sung Leee ; Hui-Young Leee ; Yoomi Chung ; Joungmok Kimg ; Masaaki Komatsuf ; Yong-ho Leed ; yholee@yuhs.ac" class="auth_mail" title="E-mail the corresponding author ; Soo Han Baeb ; soohanbae@yuhs.ac" class="auth_mail" title="E-mail the corresponding author
- 刊名：Free Radical Biology and Medicine
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：99
- 期：Complete
- 页码：520-532
- 全文大小：3862 K
文摘
- •
Ezetimibe acts as a potent Nrf2 activator without causing cytotoxicity.
- •
Ezetimibe-induced Nrf2 activation is mainly dependent on phosphorylation of p62.
- •
AMPK is required for ezetimibe-induced phosphorylation of p62 and Nrf2 activation.
- •
Ezetimibe protects mice from nonalcoholic steatohepatitis through Nrf2 activation.